Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.

People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...

The results of a pilot study suggest long term exposure to higher pollen levels leads to worse symptoms and quality of life for patients with chronic rhinosinusitis. For the 103 patients ...

This image shows a section of sinus tissue with mast cells accumulating in the center (purple). A new study from UC San Diego has found that Veterans with chronic rhinosinusitis from airborne toxins ...

Women using estrogen-containing contraceptives vs. not using any systemic hormonal contraceptives had reduced odds for ...

Researchers have discovered in a new research that COVID-19 infection is associated with an increased risk of a subsequent diagnosis of chronic rhinosinusitis (CRS). This suggests a possible ...

A comprehensive new study analyzing data from nearly 240,000 women has found that estrogen-containing hormonal contraceptives are associated with a significantly lower risk of chronic rhinosinusitis ...

Researchers at UCSD hope the study is a step closer "toward targeted therapies for patients who currently have few options." ...

The predictive variables assessed were age at EGPA diagnosis, baseline eosinophil count, history of chronic sinusitis prior to diagnosis, and glucocorticoid-treated asthma at diagnosis.

Tree pollen, one of the season’s earliest and most persistent triggers, has already started to make its presence known. In our area, experts say pollen counts spike in late February through April.

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and ...

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc. REGN and Sanofi SA SNY partnered ...